摘要
目的 研究生长抑素 (SS)、血管活性肠肽 (VIP)与心钠素 (ANP)在门脉高压症发病中的作用。 方法 应用放射免疫学方法对 30例门脉高压症患者、30例正常对照者血浆及 2 0份门脉高压性腹水进行 SS、VIP与ANP的检测。 结果 门脉高压症组血浆 SS、VIP与 ANP水平分别为 6 1.2 3± 2 3.85 ,17.6 5± 4.75及 2 0 2 .95±35 .82 pg/ ml,正常对照组分别为 81.2 3± 41.89,13.33± 3.2 9及 97.95± 36 .5 7pg/ ml,二者差别有显著性 (P <0 .0 5 ) ,腹水组分别为 16 4.0 3± 5 8.41,14.92± 3.78及 12 5 .43± 5 0 .0 4pg/ ml,腹水 SS、ANP高于对照组血浆含量(P<0 .0 5 ) ,腹水 VIP与对照组血浆含量差异无显著性。门脉高压症伴腹水者血浆 SS低于无腹水者 ,而 VIP与ANP水平高于无腹水者 (P<0 .0 5 )。 结论 血浆 SS、VIP与 ANP在肝硬化门脉高压症的病理生理机制中起一定作用。
Objective\ To study the effects of somatostatin(SS),vasoactive intestinal peptide(VIP) and atrial netriuretic peptide(ANP) in patients with portal hypertension.\ Methods\ The level of SS,VIP and ANP in blood plasma were assayed by radioimmunoassay(RIA) from 30 patients with portal hypertension and 30 controls,20 samples of ascitis from these patients were also detected.\ Results\ The level of SS,VIP and ANP in patients with portal hypertension were 61 23±23 85, 17 65±4 75 and 202 95±35 82 pg/ml respectively.\ The levels in normal control were 81 23±41 89, 13 33±3 29 and 97 95±36 57 pg/ml respectively.\ The levels in ascites were 164 03±58 41, 14 92±3 78 and 125 43±50 04 pg/ml respectively.\ The level of SS in patients was lower than that of normal control(P<0 05),while the level of VIP and ANP were higher than those of normal controls(P<0 01); the level of SS in patients with ascites was lower than that of without ascites,while the level of VIP and ANP were higher than that of without ascites.\ Conclusion\ SS,VIP and ANP play an important role in the pathogenesis of portal hypertension.\;
出处
《福建医科大学学报》
2000年第3期234-236,共3页
Journal of Fujian Medical University
基金
福建省自然科学基金!资助项目 (C96 0 42 )
关键词
门脉高压症
生长抑素
血管活性肠肽
心钠素
portal hypertension
liver cirrhosis
somatostatin
vasoactive intestinal peptide
atrial natriuretic peptide
